Need a specific person's email?
Browse Nabriva Therapeutics plc's employee directory (about 23 employees) and reveal verified emails free.
Nabriva Therapeutics plc's most common email format is First.Last@nabriva.com (ex. John.Doe@nabriva.com), used for 87% of nabriva.com addresses. Nabriva Therapeutics plc uses 2 email patterns.
| Format | Example | Share of nabriva.com |
|---|---|---|
| First.Last@nabriva.comMost common | John.Doe@nabriva.com | |
| Last@nabriva.com | Doe@nabriva.com |
Browse Nabriva Therapeutics plc's employee directory (about 23 employees) and reveal verified emails free.
Biotechnology ResearchDublin, Ireland11-50 Employees
Nabriva Therapeutics plc is a commercial-stage biotechnology company focused on developing novel antibiotics to treat serious infections. It is headquartered in Dublin, Ireland, with offices and laboratories in Vienna, Austria and King of Prussia, Pennsylvania, and additional locations in San Diego, California, United States. The company markets Xenleta (lefamulin), approved by the FDA for oral and intravenous use, and CONTEPO (fosfomycin) for injection, for which a US NDA has been submitted for complicated urinary tract infections including acute pyelonephritis. Recent strategic actions include the sale of Contepo assets to Meitheal Pharmaceuticals in July 2024 and prior asset divestitures such as Xenleta assets transferred to Sumitomo Pharma in 2023, with an earlier Merck collaboration in 2020 to market SIVEXTRO. The organization employs between 11 and 50 people.
Most common format
First.Last@nabriva.com
Example: John.Doe@nabriva.com
Free with a LeadIQ account. No credit card.
Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.